Systematic Review and Meta-analysis on Extended-Spectrum β-lactamases Producing Klebsiella pneumoniae in Nepal.

Microbiology insights Pub Date : 2023-01-01 DOI:10.1177/11786361221145179

Manita Shyaula, Christina Khadka, Prabin Dawadi, Megha Raj Banjara

{"title":"Systematic Review and Meta-analysis on Extended-Spectrum β-lactamases Producing Klebsiella pneumoniae in Nepal.","authors":"Manita Shyaula, Christina Khadka, Prabin Dawadi, Megha Raj Banjara","doi":"10.1177/11786361221145179","DOIUrl":null,"url":null,"abstract":"Objective: This systematic review and meta-analysis aimed to assess the pool estimates of extended-spectrum β-lactamases producing K. pneumoniae (ESBL-KP) and study their drug resistance profile by evaluating the studies from Nepal.Methods: A literature search was carried out in PubMed, Google Scholar, and NepJOL to screen all articles on ESBL-KP published between 2011 and 2021 from Nepal. This review was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. Relevant data were extracted, and R language 4.2.0 software was used for statistical analysis.Results: The pooled prevalence of K. pneumoniae was 5%, while the pooled prevalence of ESBL and multidrug resistance (MDR) in K. pneumoniae were 23% and 55%, respectively. Imipenem was the drug of choice (in vitro) against ESBL-KP infection.Conclusion: Our analyses showed a high prevalence of ESBL-KP and their high resistance toward commonly used drugs. This study highlights the need for the development of new antibiotics for the management of ESBL-KP infections.","PeriodicalId":74187,"journal":{"name":"Microbiology insights","volume":"16 ","pages":"11786361221145179"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/18/cf/10.1177_11786361221145179.PMC9841864.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Microbiology insights","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/11786361221145179","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

Abstract

Objective: This systematic review and meta-analysis aimed to assess the pool estimates of extended-spectrum β-lactamases producing K. pneumoniae (ESBL-KP) and study their drug resistance profile by evaluating the studies from Nepal.

Methods: A literature search was carried out in PubMed, Google Scholar, and NepJOL to screen all articles on ESBL-KP published between 2011 and 2021 from Nepal. This review was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. Relevant data were extracted, and R language 4.2.0 software was used for statistical analysis.

Results: The pooled prevalence of K. pneumoniae was 5%, while the pooled prevalence of ESBL and multidrug resistance (MDR) in K. pneumoniae were 23% and 55%, respectively. Imipenem was the drug of choice (in vitro) against ESBL-KP infection.

Conclusion: Our analyses showed a high prevalence of ESBL-KP and their high resistance toward commonly used drugs. This study highlights the need for the development of new antibiotics for the management of ESBL-KP infections.

Abstract Image

查看原文本刊更多论文

尼泊尔产肺炎克雷伯菌的广谱β-内酰胺酶的系统评价和meta分析。

目的:本系统综述和荟萃分析旨在通过尼泊尔的研究评估产肺炎克雷伯菌(ESBL-KP)的广谱β-内酰胺酶的池估计，并研究其耐药谱。方法:在PubMed、Google Scholar和NepJOL中进行文献检索，筛选2011 - 2021年间尼泊尔发表的所有关于ESBL-KP的文章。本综述遵循系统评价和荟萃分析指南的首选报告项目进行。提取相关数据，采用R语言4.2.0软件进行统计分析。结果:肺炎克雷伯菌的总流行率为5%，肺炎克雷伯菌ESBL和耐多药(MDR)的总流行率分别为23%和55%。亚胺培南是体外抗ESBL-KP感染的首选药物。结论:我们的分析显示ESBL-KP的高流行率和对常用药物的高耐药。这项研究强调需要开发新的抗生素来管理ESBL-KP感染。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Microbiology insights

自引率

0.00%

发文量

审稿时长

8 weeks